Media Center

Partnership Between ARUP and Medicover Expands Access to Companion Diagnostic in the European Union

ARUP and Medicover have partnered to provide a new companion diagnostic test to European Union patients. The test helps identify individuals eligible for a new gene therapy for severe hemophilia A.

ARUP Laboratories Honored With 2023 Best Companies to Work For Award From Utah Business Magazine

Utah Business magazine honored ARUP Laboratories with its Best Companies to Work For award for the sixth consecutive year based on anonymous employee survey results.

ARUP Laboratories Urges FDA to Withdraw Proposed Rule Regulating Laboratory-Developed Tests

ARUP believes the FDA’s plan to regulate lab-developed tests will limit access to testing, increase costs, and face a court challenge, and is calling for collaboration to better address LDT oversight.

EU Approval of AAV5 DetectCDx™ Provides Access to Companion Diagnostic for Hemophilia A Gene Therapy

ARUP has gained a Conformité Européenne (CE) mark for AAV5 DetectCDx™ single-site use. The test will aid in determining the eligibility of non-U.S. patients for a new hemophilia A gene therapy.